NCT06676904 Neonatal Platelet Transfusion Threshold Trial
| NCT ID | NCT06676904 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NICHD Neonatal Research Network |
| Condition | Thrombocytopenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,433 participants |
| Start Date | 2025-06-13 |
| Primary Completion | 2031-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,433 participants in total. It began in 2025-06-13 with a primary completion date of 2031-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
Eligibility Criteria
Inclusion Criteria: * Gestational age of 23 0/7 to 26 6/7 weeks * Postnatal age of \< 48 hours Exclusion Criteria: * Comfort care or withdrawal of care planned * Neonatal alloimmune thrombocytopenia or suspected/confirmed congenital platelet or bleeding disorder * Receipt of platelet transfusion * No receipt of Vitamin K * Parents/guardian decline consent
Contact & Investigator
Ravi M Patel, MD
PRINCIPAL INVESTIGATOR
Emory University
Frequently Asked Questions
Who can join the NCT06676904 clinical trial?
This trial is open to participants of all sexes, aged 1 Hour or older, up to 48 Hours, studying Thrombocytopenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06676904 currently recruiting?
Yes, NCT06676904 is actively recruiting participants. Contact the research team at rmpatel@emory.edu for enrollment information.
Where is the NCT06676904 trial being conducted?
This trial is being conducted at Birmingham, United States, Palo Alto, United States, San Diego, United States, Aurora, United States and 11 additional locations.
Who is sponsoring the NCT06676904 clinical trial?
NCT06676904 is sponsored by NICHD Neonatal Research Network. The principal investigator is Ravi M Patel, MD at Emory University. The trial plans to enroll 2,433 participants.